Eli Lilly Stock Gains 10% on Strong Mounjaro and Zepbound Sales

Eli Lilly's stock rose 10% on the back of strong sales performance for its diabetes and weight loss drugs, Mounjaro and Zepbound. This increase indicates that the pharmaceutical giant is maintaining its growth momentum. The company's latest quarterly financial results revealed that sales of Mounjaro and Zepbound exceeded expectations. In particular, Zepbound's rapid market share gains in the weight loss market attracted investor attention. Analysts note that these two drugs have become a significant driver of Eli Lilly's revenues. Mounjaro is effective in treating type 2 diabetes, while Zepbound is used for obesity treatment, and both drugs are central to the company's growth strategy. This surge in Eli Lilly's stock once again demonstrates how innovative products can increase market value in the pharmaceutical sector. The company's future revenues from these products are expected to continue supporting stock performance. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 70%

The news highlights the strong performance of Eli Lilly's flagship drugs, Mounjaro and Zepbound, which drove a 10% increase in the stock price. Technical indicators support this rally: the RSI at 64.8 maintains an upward trend without entering overbought territory, the MACD remains positive above the signal line, and the price is trading above both the 20-day and 50-day moving averages. In the short term, this positive momentum is expected to continue, although the possibility of some profit-taking after the 2.1% gain in the last 24 hours should not be ruled out.

RSI 14

64.8

MACD

13.95

24h Δ

2.15%

Canlı Grafikler